Ingersoll Rand(US:IR)2026-02-13 14:02Financial Data and Key Metrics Changes - The company reported a 10% increase in revenue for Q4 2025, with organic revenue growth of 3% year-over-year, driven by both positive price and volume [9][10] - Adjusted EBITDA for Q4 was $580 million, with an adjusted EBITDA margin of 27.7%, reflecting operational durability despite margin pressure from tariffs and commercial investments [9][10] - For the full year, adjusted EBITDA was approximately $2.1 billion, with an adjusted EBITDA margin of 27.4%, and adjusted earnings per share increased by 2% to $3.34 [11] Business Line Data and Key Metrics Changes - In the ITS segment, orders increased by 9% in Q4, with organic orders growing in the low single digits, and revenue grew by 11% year-over-year [13][14] - The PST segment saw Q4 orders up 6% year-over-year, with organic orders increasing by 1%, and life science businesses delivered mid-teens organic order growth [15][16] Market Data and Key Metrics Changes - The Americas region showed low single-digit organic order growth, while EMEA experienced a mid-single-digit decline, and Asia Pacific saw low double-digit growth, particularly driven by China [14] - The company noted a strong pipeline in the life sciences market, with good funnel activity in both the U.S. and internationally [25] Company Strategy and Development Direction - The company is focused on enhancing its existing portfolio through disciplined M&A, with a robust acquisition pipeline and a strategic emphasis on recurring revenue initiatives, which exceeded $450 million in 2025 [5][6] - The recent acquisition of Scinomix is aimed at advancing the life science strategy by integrating complementary technologies [8] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about improving trends in the market, particularly in life sciences and general industrial sectors, while acknowledging ongoing challenges in certain areas [26][30] - The company anticipates total revenue growth of 2.5% to 4.5% for 2026, with adjusted EBITDA expected to be in the range of $2.13 billion to $2.19 billion [17][18] Other Important Information - The company ended 2025 with a book-to-bill ratio above 1, indicating a strong order backlog and positive momentum heading into 2026 [10][11] - Free cash flow for Q4 was $462 million, with total liquidity of $3.8 billion, allowing for continued investment in high-return opportunities [11] Q&A Session Summary Question: What sort of end market trajectory is embedded in the guidance? - Management indicated that the guidance assumes current market conditions continue, with no significant recovery embedded [24][30] Question: Are there any end markets that you're specifically worried about this year? - Management noted that headwinds from RNG, electric vehicles, and photovoltaics are largely behind them, with positive trends in China [30] Question: Can you clarify the seasonality through the year? - Management expects Q1 organic growth to be flat or slightly down, with low single-digit growth anticipated for the remainder of the year [35][36] Question: What are the expectations for cost actions or productivity gains during 2026? - Management confirmed that the guidance includes productivity actions and cost savings from restructuring efforts initiated in 2025 [80][81] Question: Can you provide some color on the life science organic growth in 2026? - Management remains encouraged by the momentum in life sciences, despite challenging comps, and expects continued contributions from recent acquisitions [98][99]